Published 2022
| Version v1
Publication
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy
Creators
- Vitello, Alessandro
- Grova, Mauro
- Pugliese, Daniela
- Rizzello, Fernando
- Lanzarotto, Francesco
- Lavagna, Alessandro
- Caccaro, Roberta
- Cappello, Maria
- Viola, Anna
- Ribaldone, Davide Giuseppe
- Principi, Mariabeatrice
- Stasi, Elisa
- Scribano, Maria Lia
- Maida, Marcello
- Soriano, Alessandra
- Bezzio, Cristina
- Bodini, Giorgia
- Mocciaro, Filippo
- Privitera, Antonio Carlo
- Simondi, Daniele
- Giuffrida, Enrica
- D'Incà, Renata
- Ricci, Chiara
- Gionchetti, Paolo
- Armuzzi, Alessandro
- Orlando, Ambrogio
- Daperno, Marco
Contributors
Others:
- Vitello, Alessandro
- Grova, Mauro
- Pugliese, Daniela
- Rizzello, Fernando
- Lanzarotto, Francesco
- Lavagna, Alessandro
- Caccaro, Roberta
- Cappello, Maria
- Viola, Anna
- Ribaldone, Davide Giuseppe
- Principi, Mariabeatrice
- Stasi, Elisa
- Scribano, Maria Lia
- Maida, Marcello
- Soriano, Alessandra
- Bezzio, Cristina
- Bodini, Giorgia
- Mocciaro, Filippo
- Privitera, Antonio Carlo
- Simondi, Daniele
- Giuffrida, Enrica
- D'Incà, Renata
- Ricci, Chiara
- Gionchetti, Paolo
- Armuzzi, Alessandro
- Orlando, Ambrogio
- Daperno, Marco
Description
Background: Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed.Patients and methods: This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results: We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (4 4.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion: Adalimumab is safe and effective for the treatment of ulcerative colitis.(c) 2021 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/1096339
- URN
- urn:oai:iris.unige.it:11567/1096339
Origin repository
- Origin repository
- UNIGE